Talis Biomedical Corporat... (TLIS)
Company Description
Talis Biomedical Corporation operates as a molecular diagnostic company.
The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases.
It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19.
In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus.
Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
| Country | United States |
| IPO Date | Feb 12, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 99 |
| CEO | Rebecca Markovich |
Contact Details
Address: 230 Constitution Drive Menlo Park, California United States | |
| Website | https://talisbio.com |
Stock Details
| Ticker Symbol | TLIS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001584751 |
| CUSIP Number | 87424L108 |
| ISIN Number | US87424L2079 |
| Employer ID | 00-0000000 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Rebecca Markovich | Interim Chief Financial Officer |
| Gillian Green | Company Secretary |
| Liang Li Ph.D. | Co-Founder and Director of Technology & Strategy |
| Margaret Barrett M.S. | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 10, 2024 | SC 13D/A | [Amend] Filing |
| Sep 30, 2024 | 15-12G | Filing |
| Sep 20, 2024 | 25-NSE | Filing |
| Sep 17, 2024 | 8-K | Current Report |
| Sep 09, 2024 | S-8 POS | Filing |
| Sep 09, 2024 | S-8 POS | Filing |
| Sep 09, 2024 | S-8 POS | Filing |
| Sep 09, 2024 | S-8 POS | Filing |
| Sep 09, 2024 | 4 | Filing |
| Sep 06, 2024 | 8-K | Current Report |